



FORMOSA BIOMEDICAL TECHNOLOGY CORP.

To whom it may concern,

We hereby would like to introduce a potential COVID-19 testing solution by Formosa Biomedical Technology Corp. from Taiwan. Formosa Biomedical Technology Corp. has developed an in-vitro diagnostic kit "One Sure SARS-CoV-2 Ag Rapid Test kit". The highlight of this kit is to provide a rapid immunochromatographic test (like the influenza testing) with high sensitivity. It needs only 15~20 minutes to detect whether there is the antigen from SARS-CoV-2 in the nasopharyngeal or oropharyngeal swab specimens. Formosa Biomedical Technology Corp. has verified that the limit of detection of SARS-CoV-2 is 88 PFU/ml and will not cross-react with other respiratory viruses, including influenza, adenovirus and so on. This product has high sensitivity and high specificity, and it is easy to operate, no instrument required, convenient and time-saving, which is very suitable and effective for the POCT screening.

Fortunately, the COVID-19 situation is under control in Taiwan. Therefore, Formosa Biomedical Technology Corp. would like to find a partner to conduct the evaluation of positive patient samples.

We would like to ask if your center (laboratory) would be interested in collaborating with Formosa Biomedical Technology Corp., for a COVID-19 test trial by the freshly collected specimen from the subjects.

I appreciate your consideration, and please reach out to either myself or directly to Formosa Biomedical Technology Corp. Through the collaboration with you, we hope this product can be a reliable tool to detect SARS-CoV-2 and prevent the epidemic spread.

Thank you.

5.1.2e

Medical Technology Div.  
Formosa Biomedical Technology Corp.  
F-5F, No.201, Tunghwa N. Road, Taipei 105, Taiwan

5.1.2e

E-mail: 5.1.2e @tpg.com.tw